Details for New Drug Application (NDA): 212135
✉ Email this page to a colleague
NDA 212135 describes IMATINIB MESYLATE, which is a drug marketed by Amneal Pharms, Apotex, Chartwell Rx, Cspc Ouyi, Dr Reddys, Eugia Pharma, Hetero Labs Ltd V, Hikma, Mylan, Natco Pharma Ltd, Novitium Pharma, Qilu Pharm Hainan, Shilpa, Sun Pharm, Teva Pharms Usa, and Zydus Pharms, and is included in sixteen NDAs. It is available from twenty suppliers. Additional details are available on the IMATINIB MESYLATE profile page.
The generic ingredient in IMATINIB MESYLATE is imatinib mesylate. There are thirty-four drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.
The generic ingredient in IMATINIB MESYLATE is imatinib mesylate. There are thirty-four drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.
Summary for 212135
| Tradename: | IMATINIB MESYLATE |
| Applicant: | Qilu Pharm Hainan |
| Ingredient: | imatinib mesylate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212135
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 212135 | ANDA | Upsher-Smith Laboratories, LLC | 0832-0532 | 0832-0532-09 | 90 TABLET in 1 BOTTLE (0832-0532-09) |
| IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 212135 | ANDA | Upsher-Smith Laboratories, LLC | 0832-0533 | 0832-0533-03 | 30 TABLET in 1 BOTTLE (0832-0533-03) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jun 21, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 400MG BASE | ||||
| Approval Date: | Jun 21, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
